Exagen Inc. (NASDAQ:XGN) Short Interest Down 42.0% in April

Exagen Inc. (NASDAQ:XGN) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 11,900 shares, a decrease of 42.0% from the March 31st total of 20,500 shares. Based on an average daily volume of 38,200 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Exagen

Institutional investors have recently modified their holdings of the company. Perkins Capital Management Inc. grew its position in shares of Exagen by 92.8% during the fourth quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock worth $1,013,000 after acquiring an additional 245,000 shares during the last quarter. Stonepine Capital Management LLC grew its position in shares of Exagen by 14.7% during the third quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock worth $2,912,000 after acquiring an additional 154,139 shares during the last quarter. Finally, RTW Investments LP grew its position in shares of Exagen by 0.8% during the fourth quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after acquiring an additional 12,170 shares during the last quarter. Institutional investors own 75.25% of the company’s stock.

Exagen Stock Up 0.7 %

Shares of NASDAQ:XGN opened at $1.42 on Friday. The stock has a market capitalization of $24.48 million, a price-to-earnings ratio of -1.06 and a beta of 1.19. Exagen has a 1-year low of $1.30 and a 1-year high of $3.92. The company’s fifty day moving average is $1.68 and its two-hundred day moving average is $1.77. The company has a debt-to-equity ratio of 0.85, a quick ratio of 4.02 and a current ratio of 4.02.

Exagen (NASDAQ:XGN) last issued its earnings results on Monday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.02). The business had revenue of $13.77 million for the quarter, compared to analyst estimates of $11.43 million. Exagen had a negative return on equity of 80.28% and a negative net margin of 45.08%. During the same period last year, the company posted ($0.58) earnings per share. Equities analysts anticipate that Exagen will post -1.46 EPS for the current year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).